Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221077039
Abstract: Introduction Management of elderly patients with cancer has become a global issue. We investigated the safety and tolerability of lenvatinib in hepatocellular carcinoma (HCC) patients ≥80 years old. Methods We retrospectively evaluated 61 HCC patients… read more here.
Keywords: elderly patients; group; elderly group; years old ... See more keywords
The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "In Vivo"
DOI: 10.21873/invivo.12775
Abstract: Background/Aim: We aimed to investigate the association between The Geriatric Nutritional Risk Index (GNRI) and the tolerability of lenvatinib in patients with hepatocellular carcinoma (HCC). Patients and Methods: We retrospectively evaluated 61 HCC patients treated… read more here.
Keywords: gnri; lenvatinib; tolerability lenvatinib; lenvatinib patients ... See more keywords